10 May 2022
Supply of abatacept is improving. Following collaboration between the the Australian Rheumatology Association (ARA), the Therapeutic Goods Administration (TGA), Bristol-Myers Squibb Australia Pty Ltd (BMS) and Arthritis Australia, specialists have been advised they can increase the use of intravenous (IV) infusion abatacept in some patient groups.
To help patients as supply returns, the TGA extended the Serious Scarcity Substitution Instrument (SSSI) until 30 June 2022.
If you have questions about your current treatment, please contact your specialist.
More information about the abatacept shortage for patients can be found on the TGA website here.
The recording of the consumer webinar held on Wednesday 2nd March is available on Arthritis Australia's website here.
Topic: Arthritis Australia, TGA, ARA and BMS Abatacept Shortage Webinar for Consumers
Catherine Hill, Australian Rheumatology Association
Elspeth Kay, Therapeutic Goods Administration
Neil MacGregor, Bristol-Myers Squibb Australia
Louise Hardy, Arthritis Australia
Further information and support
Arthritis Australia: Infoline 1800 011 041 arthritisaustralia.com.au
For ARA Members more information and a recording of the ARA webinar is available here.